(R)-3-(2-(6-(5-chloro-2-methoxybenzyl)-3-(2,2-dimethylhydrazono)-7-oxo-1,4-diazepan-1-yl)acetamido)benzoic acid hydrochloride

ID: ALA4128173

Chembl Id: CHEMBL4128173

PubChem CID: 145961109

Max Phase: Preclinical

Molecular Formula: C24H29Cl2N5O5

Molecular Weight: 501.97

Molecule Type: Small molecule

Associated Items:

Names and Identifiers

Canonical SMILES:  COc1ccc(Cl)cc1C[C@@H]1CN/C(=N\N(C)C)CN(CC(=O)Nc2cccc(C(=O)O)c2)C1=O.Cl

Standard InChI:  InChI=1S/C24H28ClN5O5.ClH/c1-29(2)28-21-13-30(14-22(31)27-19-6-4-5-15(11-19)24(33)34)23(32)17(12-26-21)9-16-10-18(25)7-8-20(16)35-3;/h4-8,10-11,17H,9,12-14H2,1-3H3,(H,26,28)(H,27,31)(H,33,34);1H/t17-;/m1./s1

Standard InChI Key:  OYVPOOBKAUXRGD-UNTBIKODSA-N

Associated Targets(Human)

KLK7 Tchem Kallikrein 7 (657 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
KLK5 Tchem Kallikrein 5 (307 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
PRSS1 Tclin Trypsin (2137 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

Klk7 Kallikrein-7 (46 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 501.97Molecular Weight (Monoisotopic): 501.1779AlogP: 2.15#Rotatable Bonds: 8
Polar Surface Area: 123.57Molecular Species: ACIDHBA: 6HBD: 3
#RO5 Violations: 1HBA (Lipinski): 10HBD (Lipinski): 3#RO5 Violations (Lipinski): 1
CX Acidic pKa: 3.92CX Basic pKa: 7.46CX LogP: -0.28CX LogD: -0.53
Aromatic Rings: 2Heavy Atoms: 35QED Weighted: 0.47Np Likeness Score: -0.88

References

1. Murafuji H, Sugawara H, Goto M, Oyama Y, Sakai H, Imajo S, Tomoo T, Muto T..  (2018)  Structure-based drug design to overcome species differences in kallikrein 7 inhibition of 1,3,6-trisubstituted 1,4-diazepan-7-ones.,  26  (12): [PMID:29884582] [10.1016/j.bmc.2018.05.044]
2. Murafuji H, Sakai H, Goto M, Imajo S, Sugawara H, Muto T..  (2017)  Discovery and structure-activity relationship study of 1,3,6-trisubstituted 1,4-diazepane-7-ones as novel human kallikrein 7 inhibitors.,  27  (23): [PMID:29102227] [10.1016/j.bmcl.2017.10.030]
3. Murafuji H, Sakai H, Goto M, Oyama Y, Imajo S, Sugawara H, Tomoo T, Muto T..  (2018)  Structure-based drug design of 1,3,6-trisubstituted 1,4-diazepan-7-ones as selective human kallikrein 7 inhibitors.,  28  (8): [PMID:29550094] [10.1016/j.bmcl.2018.03.011]

Source